Merck invests €300 million in Daejeon biopharmaceutical production center
AI Summary- Merck is building a new biopharmaceutical production center in Daejeon, South Korea.
- The project represents a €300 million ($337 million) investment, Merck’s largest life science investment in Asia-Pacific.
- Merck’s strategy seeks to reduce reliance on U.S. and European manufacturing sites while serving Asia’s biotech market.